Vaccine Development Against HIV-1: Current Perspectives and Future Directions

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2002 Mar 1

PMID 11868934

Citations 4

Authors

Rebecca L Edgeworth

Juan Homero San

Jason A Rosenzweig

Nang L Nguyen

Jean D Boyer

Kenneth E Ugen

Affiliations

Soon will be listed here.

Abstract

The development of an efficacious vaccine against the human immunodeficiency virus (HIV) is of great urgency, because it is accepted that vaccination is the only means capable of controlling the AIDS pandemic. The foundation of HIV vaccine development is the analysis of immune responses during natural infection and the utilization of this knowledge for the development of protective immunization strategies. Initial vaccine development and experimentation are usually in animal models, including murine, feline, and nonhuman primates. Experimental vaccine candidates are closely studied for both efficacy and safety before proceeding to human clinical trials. There are a number of different therapeutic and prophylactic vaccine strategies currently being studied in human clinical trials. Vaccine strategies that are being tested, or have previously been tested, in humans include subunit, DNA plasmid, and viral vector, and combinations of these various strategies. Some of the results of these trials are promising, and additional research has focused on the development of appropriate chemical and genetic adjuvants as well as methods of vaccine delivery to improve the host immune response. This review summarizes the vaccine strategies that have been tested in both animal models and human clinical trials.

Citing Articles

CD25 preselective anti-HIV vectors for improved HIV gene therapy.

Kalomoiris S, Lawson J, Chen R, Bauer G, Nolta J, Anderson J Hum Gene Ther Methods. 2012; 23(6):366-75.

PMID: 23216020 PMC: 4015076. DOI: 10.1089/hgtb.2012.142.

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Liao J, Gregor P, Wolchok J, Orlandi F, Craft D, Leung C Cancer Immun. 2006; 6:8.

PMID: 16626110 PMC: 1976276.

HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion.

Roberts K, Newman P, Duan N, Rudy E J Natl Med Assoc. 2006; 97(12):1662-71.

PMID: 16396058 PMC: 2640722.

Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Harvey T, Anraku I, Linedale R, Harrich D, Mackenzie J, Suhrbier A J Virol. 2003; 77(14):7796-803.

PMID: 12829819 PMC: 161953. DOI: 10.1128/jvi.77.14.7796-7803.2003.

References

Cafaro A, Caputo A, Fracasso C, Maggiorella M, Goletti D, Baroncelli S . Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med. 1999; 5(6):643-50. DOI: 10.1038/9488. View

Caselli E, Betti M, Grossi M, Balboni P, Rossi C, Boarini C . DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol. 1999; 162(9):5631-8. View

Sei S, Sandelli S, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price L . Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis. 1999; 180(3):626-40. DOI: 10.1086/314944. View

Xin K, Hamajima K, Sasaki S, Tsuji T, Watabe S, Okada E . IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine. 1999; 17(7-8):858-66. DOI: 10.1016/s0264-410x(98)00271-0. View

Igarashi T, Shibata R, Hasebe F, Ami Y, Shinohara K, Komatsu T . Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res Hum Retroviruses. 1994; 10(8):1021-9. DOI: 10.1089/aid.1994.10.1021. View

Willett B, Flynn J, Hosie M . FIV infection of the domestic cat: an animal model for AIDS. Immunol Today. 1997; 18(4):182-9. DOI: 10.1016/s0167-5699(97)84665-8. View

Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S . HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995; 1(1):59-64. DOI: 10.1038/nm0195-59. View

Calarota S, Leandersson A, Bratt G, Hinkula J, Klinman D, Weinhold K . Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol. 1999; 163(4):2330-8. View

Gorse G, Patel G, Mandava M, BERMAN P, Belshe R . MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1999; 15(10):921-30. DOI: 10.1089/088922299310638. View

10.

Joag S, Li Z, Wang C, Jia F, FORESMAN L, Adany I . Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques. J Med Primatol. 1998; 27(2-3):59-64. DOI: 10.1111/j.1600-0684.1998.tb00227.x. View

11.

Fast P, Walker M . Human trials of experimental AIDS vaccines. AIDS. 1993; 7 Suppl 1:S147-59. View

12.

Kim J, Bagarazzi M, Trivedi N, Hu Y, Kazahaya K, Wilson D . Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol. 1997; 15(7):641-6. DOI: 10.1038/nbt0797-641. View

13.

Sasaki S, Fukushima J, Hamajima K, Ishii N, Tsuji T, Xin K . Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin Exp Immunol. 1998; 111(1):30-5. PMC: 1904860. DOI: 10.1046/j.1365-2249.1998.00466.x. View

14.

Desrosiers R . The simian immunodeficiency viruses. Annu Rev Immunol. 1990; 8:557-78. DOI: 10.1146/annurev.iy.08.040190.003013. View

15.

Ihata A, Watabe S, Sasaki S, Shirai A, Fukushima J, Hamajima K . Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology. 1999; 98(3):436-42. PMC: 2326951. DOI: 10.1046/j.1365-2567.1999.00879.x. View

16.

Clements J, Montelaro R, Zink M, Amedee A, Miller S, Trichel A . Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol. 1995; 69(5):2737-44. PMC: 188966. DOI: 10.1128/JVI.69.5.2737-2744.1995. View

17.

Corey L, McElrath M, Weinhold K, Matthews T, Stablein D, Graham B . Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis. 1998; 177(2):301-9. DOI: 10.1086/514202. View

18.

Evans T, Keefer M, Weinhold K, Wolff M, Montefiori D, Gorse G . A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis. 1999; 180(2):290-8. DOI: 10.1086/314895. View

19.

BERMAN P, Gregory T, Riddle L, NAKAMURA G, Champe M, Porter J . Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990; 345(6276):622-5. DOI: 10.1038/345622a0. View

20.

Boyer J, Ugen K, Chattergoon M, Wang B, Shah A, Agadjanyan M . DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. J Infect Dis. 1997; 176(6):1501-9. DOI: 10.1086/514148. View